)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Pliant Therapeutics
Pliant Therapeutics (PLRX) investor relations material
Pliant Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary12 Nov, 2026
Executive summary
PLN-101095 FORTIFY Phase 1b enrollment is ahead of schedule; interim data are expected in 2027.
Integrin-mediated siRNA delivery showed >75% target-gene knockdown at eight weeks in non-human primates, with selective delivery to targeted extrahepatic tissues.
Q3 net loss narrowed to $24.4M from $26.3M YoY; 9M net loss fell to $66.8M from $125.8M, mainly reflecting lower spending after bexotegrast discontinuation and restructuring.
Financial highlights
Q3 2026 operating expenses were $25.7M vs. $28.3M YoY; R&D was $17.9M vs. $17.9M and G&A was $7.8M vs. $10.3M.
9M 2026 operating expenses were $71.4M vs. $132.8M YoY; R&D was $48.2M vs. $93.6M and G&A was $23.1M vs. $39.2M.
Q3 net loss per share was $0.39 vs. $0.43 YoY; 9M loss per share was $1.08 vs. $2.05.
Q3 interest and other income was $1.4M vs. $2.8M YoY; interest expense was zero vs. $0.8M in Q3 2025.
Outlook and guidance
Cash, cash equivalents and short-term investments of $142.6M at September 30, 2026, were expected to fund operations to mid-2028.
R&D expense is expected to remain relatively consistent near term, increasing with PLN-101095 Phase 1b progress; G&A expense is expected to remain relatively consistent.
FORTIFY is enrolling up to 102 patients across NSCLC, clear cell renal cell carcinoma and high-TMB cohorts; interim data are expected in 2027.
The auction and disposal of held-for-sale assets are expected to conclude by December 31, 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Pliant Therapeutics
- Net loss narrows, cash runway extends into 2028, and FORTIFY trial advances toward 2027 data.PLRX
Q2 2026 - Bexotegrast showed strong efficacy and safety in IPF, with pivotal trial and funding secured through 2026.PLRXH.C. Wainwright 26th Annual Global Investment Conference 2024
- Durable oncology responses and advancing siRNA delivery platform set up major 2026–2027 milestones.PLRXRBC Capital Markets Global Healthcare Conference 2026
- Lower net loss and strong cash reserves support advancing oncology pipeline.PLRXQ1 2026
- Vote on directors, executive pay, and auditor at the June 2026 virtual annual meeting.PLRXProxy filing
- Proxy covers director elections, executive pay, auditor ratification, and governance updates.PLRXProxy filing
- Biotech seeks up to $300M via shelf/ATM to fund R&D, with high risk and broad use of proceeds.PLRXRegistration filing
- PLN-101095 advances to Phase 1b after strong Phase 1 data; net loss narrows on lower expenses.PLRXQ4 2025
- Durable responses and safety in ICI-refractory tumors drive Phase 1b expansion and pipeline growth.PLRXPiper Sandler 37th Annual Healthcare Conference
Next Pliant Therapeutics earnings date
Q4 20262 Mar, 2027
Pliant Therapeutics
Next Pliant Therapeutics earnings date
Q4 20262 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Pliant Therapeutics, Inc. (PTI) is a clinical stage biopharmaceutical company developing DNA-based therapeutics that enable patients to reverse fibrosis and related diseases. The company's lead product candidate, PRTX-100, is a proprietary plasmid DNA therapeutic that has completed Phase 2 testing in nonalcoholic steatohepatitis (NASH). PTI owns the rights to exclusive plasmid-based therapies optimized for solid tumors including breast and pancreatic cancers. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.